Related Experiment Video

Updated: Jul 1, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer

Maurizio Chiriva-Internati1, Jon A Weidanz, Yuefei Yu

  • 1Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, Lubbock, TX 79430-6591, USA. maurizio.chiriva@ttuhsc.edu

Journal of Immunotherapy (Hagerstown, Md. : 1997)
|September 10, 2008
PubMed

Insights

Adoptive immunotherapy targeting sperm protein 17 eradicated metastatic ovarian cancer (OC) in mice. This approach, using T cells specific for sperm protein 17, showed efficacy and safety without autoimmunity.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Standard treatments for advanced ovarian cancer (OC) lack efficacy and cause side effects.
  • Adoptive immunotherapy using immune system components offers a promising alternative for cancer treatment.

Purpose of the Study:

  • To investigate the efficacy of adoptive immunotherapy targeting sperm protein 17 (Sp17) for human metastatic OC.
  • To evaluate the safety profile of this immunotherapy approach in a preclinical mouse model.

Main Methods:

  • Utilized a human OC cell line (SK-OV-3A2.A3) expressing Sp17 to induce tumors in immunodeficient mice.
  • Applied in vitro cultured monoclonal cytotoxic T lymphocytes (CTLs) specific for Sp17, derived from OC patients and healthy donors.
  • Assessed tumor eradication and examined tissue sections for signs of autoimmunity.

Main Results:

  • Demonstrated that Sp17-specific CTLs effectively eradicated human metastatic OC cells in vivo.
  • Provided the first direct evidence of successful tumor eradication using this targeted immunotherapy.
  • Histological examination revealed no evidence of autoimmunity, supporting the safety of the approach.

Conclusions:

  • Adoptive immunotherapy targeting Sp17 is a potentially effective and safe treatment strategy for metastatic ovarian cancer.
  • This approach holds promise for improving outcomes in patients with advanced or treatment-resistant OC.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...